Taking stock of the drug industry, from the lab to the medicine chestOctober 21, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Joe Raedle/Getty Images STAT+ | Behind CVS CEO's ouster, a question: Do a pharmacy and a health insurer make sense together? CVS Health is running out of time to answer an existential question about its strategy, as investors clamor for a turnaround. By Matthew Herper STAT+ | Catalent tries to reassure customers about its deal with Novo Holdings The CEO insisted the company will operate as an "independent, full-service contract development and manufacturing organization." By Ed Silverman STAT+ | Pharma execs donated more to Democrats in campaign's final stretch A STAT review of contributions by CEOs and others showed most executives just gave to their companies' political action committees. By Rachel Cohrs Zhang Adobe STAT+ | Seaport Therapeutics adds another $225 million to coffers to embrace the 'golden age of neuroscience' "We're in the golden age of neuroscience, and neuropsychiatry, in particular," said Daphne Zohar, the CEO of the Boston-based company. By Allison DeAngelis STAT+ | Perplexing results from Duchenne muscular dystrophy trial raise questions about gene therapies Clinical trial results show boys did not improve even though a biomarker target was achieved, which suggests an FDA standard is inadequate. By Jason Mast and Adam Feuerstein More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments